home / stock / ucbjy / ucbjy quote
Last: | $75.6849 |
---|---|
Change Percent: | -0.26% |
Open: | $75.88 |
Close: | $75.88 |
High: | $75.88 |
Low: | $75.09 |
Volume: | 21,447 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$75.6849 | $75.88 | $75.88 | $75.88 | $75.09 | 21,447 | 07-03-2024 |
$75.88 | $75.52 | $75.88 | $76.03 | $75.52 | 21,387 | 07-02-2024 |
$75.2 | $76.5 | $75.2 | $76.67 | $75.12 | 7,528 | 07-01-2024 |
$74.13 | $73.84 | $74.13 | $74.31 | $73.84 | 17,818 | 06-28-2024 |
$73.74 | $73.84 | $73.74 | $73.84 | $73.515 | 7,446 | 06-27-2024 |
$73.09 | $72.76 | $73.09 | $73.197 | $72.63 | 17,716 | 06-26-2024 |
$73.121 | $73.722 | $73.121 | $73.722 | $73 | 52,533 | 06-25-2024 |
$74.38 | $74 | $74.38 | $74.55 | $73.96 | 47,774 | 06-24-2024 |
$74.358 | $73.76 | $74.358 | $74.405 | $73.49 | 10,270 | 06-21-2024 |
$73.275 | $72.99 | $73.275 | $73.62 | $72.99 | 44,060 | 06-20-2024 |
$74.63 | $74.2727 | $74.63 | $74.63 | $74.246 | 18,605 | 06-19-2024 |
$74.63 | $74.2727 | $74.63 | $74.63 | $74.246 | 18,605 | 06-18-2024 |
$73.768 | $73.5 | $73.768 | $73.81 | $73.414 | 12,998 | 06-17-2024 |
$73.745 | $73.35 | $73.745 | $73.84 | $73.32 | 14,894 | 06-14-2024 |
$73.075 | $73.1799 | $73.075 | $73.23 | $72.94 | 14,227 | 06-13-2024 |
$72.89 | $72.64 | $72.89 | $73.32 | $72.11 | 8,244 | 06-12-2024 |
$70.68 | $69.76 | $70.68 | $70.7 | $69.12 | 17,673 | 06-11-2024 |
$70.09 | $69.3 | $70.09 | $70.09 | $69.3 | 4,915 | 06-10-2024 |
$70.25 | $70.335 | $70.25 | $70.38 | $70.25 | 8,705 | 06-07-2024 |
$70.795 | $70.811 | $70.795 | $71.07 | $70.64 | 24,879 | 06-06-2024 |
News, Short Squeeze, Breakout and More Instantly...
UCB S.A. ADR Company Name:
UCBJY Stock Symbol:
OTCMKTS Market:
FINTEPLA® (fenfluramine) Results Examining its Impact in Managing Generalized Tonic-Clonic Seizures in Developmental and Epileptic Encephalopathies Published in Epilepsia PR Newswire FINTEPLA is approved by the U.S. Food and Drug Administration (FDA) for the treatment of ...
New CIMZIA® data for women living with chronic rheumatic diseases throughout pregnancy, and for people living with RA and high rheumatoid factor levels PR Newswire Pharmacokinetic data from the CHERISH study suggest that pregnant women treated with certolizumab pegol can ...
UCB to share first presentations of BIMZELX® (bimekizumab-bkzx) two-year data in axial spondyloarthritis and psoriatic arthritis at EULAR 2024 PR Newswire Patients with non-radiographic axial spondyloarthritis (nr-axSpA) and those with ankylosing spondylitis (AS) treated ...